Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2Phase 3 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Thoracic 1Other hematologic neoplasm 1

Conditions

Lymphoma, T-Cell, Peripheral 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × HBI-8000 × Clear all
NCT05141357 2025-12-24

HBI-8000

HUYABIO International, LLC.

Phase 2 Terminated
5 enrolled 8 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05833724 2025-03-11

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Great Novel Therapeutics Biotech & Medicals Corporation

Phase 2 Recruiting
33 enrolled
Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

NCT02953652 2024-09-19

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

HUYABIO International, LLC.

Phase 2 Completed
55 enrolled 18 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT02955589 2024-09-19

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)

HUYABIO International, LLC.

Phase 2 Completed
23 enrolled 15 charts
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡